Detalhe da pesquisa
1.
Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study.
J Neurol Neurosurg Psychiatry
; 93(3): 254-262, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34845002
2.
Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions.
Cephalalgia
; 42(8): 749-760, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35272533
3.
Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study.
Cephalalgia
; 41(11-12): 1262-1267, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33939497
4.
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial.
Eur J Neurol
; 28(5): 1716-1725, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33400330
5.
Timing and durability of response to erenumab in patients with episodic migraine.
Headache
; 61(10): 1553-1561, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34841526
6.
Timing and durability of response to erenumab in patients with chronic migraine.
Headache
; 61(8): 1255-1263, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34363708
7.
Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open-label, multiple-dose study.
Clin Transl Sci
; 17(3): e13755, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38476099
8.
Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials.
JAMA Neurol
; 79(2): 159-168, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34928306
9.
Long-Term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study.
Neurology
; 2021 Apr 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-33910942